United States v. Johnson
Headline: Ruling narrows federal food-and-drug law, holding that cure claims are not “misbranding” unless labels falsely state an item’s identity or ingredients, making prosecutions for mere false praise harder on interstate sellers.
Holding:
- Makes it harder to prosecute false medical cure claims under the Food and Drugs Act.
- Keeps enforcement focused on identity, ingredients, strength, and origin disclosures.
- Leaves other legal remedies available for fraudulent medicines.
Summary
Background
A seller shipped bottles and packages of medicine from Missouri to Washington, D.C., labeled as cures for cancer and other serious illnesses. The labels used names like “Cancerine” and “Blood Purifier” and promised removal of disease and healing of sores, while the indictment alleged the seller knew the claims were false. A federal judge quashed the indictment under the Food and Drugs Act, and the government asked the high court to decide whether those advertising claims fit the Act’s definition of “misbranded.”
Reasoning
The central question was whether the statute’s ban on false or misleading statements covers claims about what a product will cure or only statements that identify what the product actually is. Justice Holmes’s opinion interpreted “statement…regarding such article, or the ingredients or substances contained therein which shall be false or misleading” as aimed primarily at identity, ingredients, strength, quality, purity, or place of manufacture. The Court emphasized the Act’s listed examples and the role of the Bureau of Chemistry in deciding ingredient issues, and concluded mere laudatory or prophetic claims about effects do not fall within the misbranding clause. The Court therefore affirmed the dismissal.
Real world impact
The decision restricts federal misbranding prosecutions for sellers who make false cure claims unless labels also falsify identity or ingredient facts. Enforcement under the Act will remain focused on ingredient disclosure, quantities, and origin, as determined administratively. The ruling does not foreclose other laws or remedies, and it does not address broader constitutional questions.
Dissents or concurrances
A dissent argued Congress intended a broader reach, citing legislative history and prior prosecutions; it urged that demonstrably false cure claims should be punishable under the Act.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?